Nucleolar protein NOP2 could serve as a potential prognostic predictor for clear cell renal cell carcinoma

Wang, Gang; Qu, Fangfang; Liu, Shouyong; Zhou, Jinqiu; Wang, Yi

doi:10.1080/21655979.2021.1960130

Cited by 21 publications

(20 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A trend was also observed that the later the tumor stage, the higher the expression of NOP2, especially in ACC and KIRC. Consistent with our results, Wang et al (2021 ) demonstrated significant associations between high NOP2 expression and age and tumor stage in KIRC. However, NOP2 expression was not related to age, gender, and tumor stage in resected LUAD, which was not in accordance with our study ( Sato et al, 1999 ).…”

Section: Discussionsupporting

confidence: 91%

Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types

Liu

Zhang

Lin

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Recent studies have identified that RNA 5-methylcytosine (m5C) is a wide-spread epigenetic modification in tumorigenesis. However, the clinical and immunotherapeutic values of m5C regulator NOP2 in 33 cancers remain unclear.Methods: The mRNA expression data and clinical data of 33 cancers were downloaded from The Cancer Genome Atlas (TCGA) database. The immunotherapy data including GSE67501, GSE78220, GSE35640, and IMvigor210 were downloaded from the Gene Expression Omnibus (GEO) database and the website based on the Creative Commons 3.0 license (http://research-pub.Gene.com/imvigor210corebiologies). The expression, survival, clinical parameters, tumor mutation burden (TMB), microsatellite instability (MSI), and tumor microenvironment (TME) were evaluated. Finally, the relationship between NOP2 and immunotherapy response was further explored.Results: NOP2 was significantly upregulated in most cancers, and high NOP2 expression was associated with poor prognosis. TMB, MSI, and NOP2 activities were involved in the dysregulation of NOP2. NOP2 was closely associated with immune cell infiltration, immune modulators, and immunotherapeutic inactivation.Conclusions: We comprehensively explored the clinical and immunotherapeutic values of NOP2 in cancers, providing evidence regarding the function of NOP2 and its role in clinical treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types

Liu

Zhang

Lin

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…A 12-gene signature related to iron metabolism was developed in lung cancer [ 87 ]. NOP2 expression was found to be related to stage, age, grade and prognosis in RCC [ 88 ]. HSF1 was observed upregulated in multiple cancers and might be a potential target for immunotherapy [ 89 ].…”

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers

Tang

Wang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Beta-actin (ACTB), a highly conserved cytoskeleton structural protein, has been regarded as a common housekeep gene and used as a reference gene for years. However, accumulating evidence indicates that ACTB is abnormally expressed in multiple cancers and hence changes the cytoskeleton to affect the invasiveness and metastasis of tumors. This study aimed to investigate the function and clinical significance of ACTB in pan-cancer. The role of ACTB for prognosis and immune regulation across 33 tumors was explored based on the datasets of gene expression omnibus and the cancer genome atlas. Differential expression of ACTB was found between cancer and adjacent normal tissues, and significant associations was found between ACTB expression and prognosis of tumor patients. In most cancers, ACTB expression was associated with immune cells infiltration, immune checkpoints and other immune modulators. Relevance between ACTB and metastasis and invasion was identified in various types of cancers by CancerSEA. Moreover, focal adhesion and actin regulation-associated pathways were included in the functional mechanisms of ACTB. The expression of ACTB was verified by quantitative real-time polymerase chain reaction. Knockdown of ACTB inhibited head and neck squamous carcinoma cell migration and invasion by NF-κB and Wnt/β-catenin pathways. Our first pan-cancer study of ACTB offers insight into the prognostic and immunological roles of ACTB across different tumors, indicating ACTB may be a potential biomarker for poor prognosis and immune infiltration in cancers, and the role of ACTB as a reference gene in cancers was challenged.

show abstract

“…We detected a high NOP2, also known as NSUN1, mRNA level in PRAD samples which ties well with previous findings. The amplification of NOP2 and its overexpression is frequently found in renal cell carcinoma (RCC) [52]. Increased NOP2 expression in diverse cancer types such as LUAD, LUSC, adrenocortical carcinoma, and ovarian serous cystadenocarcinoma was described in a reported pan-cancer study [53].…”

Section: Discussionmentioning

confidence: 99%

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

Kahyaoğulları

Demircan

2021

Preprint

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. Expanding evidence suggests a significant association between cancer progression and RNA modifications. However, our knowledge of the link between m5C and hm5C pathways with PCa is limited. Therefore, we aimed to explore the diagnostic and prognostic values of m5C and hm5C regulators in PCa. In this study, genetic alterations in m5C and hm5C regulators were identified using publicly available databases. Differentially expressed genes in these pathways between tumor and nontumor samples, correlation among m5C and hm5C pathway members, and prognostic value of the regulators were evaluated. Furthermore, enrichment of gene ontology (GO) terms and KEGG pathways was carried out. Obtained results unveiled the mRNA level differences as the key genetic alterations for m5C and hm5C regulators between tumor and nontumor samples. UHRF1, TET3, and NEIL1 were significantly upregulated in tumor samples compared to nontumor ones, whereas EGR1 was significantly downregulated. UHRF1, DNMT1, NSUN2, NSUN4, C1orf77, C3orf37, WDR77, NEIL1, and TDG genes were identified as candidate prognostic markers of overall survival. The upregulated genes in patient samples with genetic alterations in m5C and hm5C pathways enriched cell cycle-related processes. In summary, our findings suggest that the m5C and hm5C regulators might play a role in PRAD development by activation of proliferation, and the UHRF1, NSUN2, and NEIL1 genes have the potential to be utilized as clinical biomarkers.

show abstract

Nucleolar protein NOP2 could serve as a potential prognostic predictor for clear cell renal cell carcinoma

Cited by 21 publications

References 56 publications

Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types

Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types

A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

Contact Info

Product

Resources

About